LONDON, ON, Dec. 22 /PRNewswire/ - Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384. These patents join a portfolio of more than 80 previously-granted patents for Viron's multiple therapeutic candidates. Viron's unique drug discovery platform identifies proteins expressed by non-human viruses that have evolved over millions of years of evolutionary selection to evade their host's immune system, endowing them with powerful immuno-modulatory and anti-inflammatory properties.
The new patent, US 7,514,405, entitled "Methods for treating transplant rejection," covers the treatment of chronic transplant rejection by administering VT-111 in combination with an immunosuppressant, such as cyclosporine. "This patent extends protection for VT-111 in transplant out to at least 2021," said Kevin Sullivan, Vice President of Business Development for Viron Therapeutics. "This provides ample time for us to unlock the commercial potential arising from upcoming organ transplant trials." Viron will pursue the transplant indication in parallel with Acute Coronary Syndromes (ACS) for VT-111, due to the significant unmet medical need in this space and the resulting rapid regulatory path forward. There are currently no therapeutic molecules targeting chronic organ rejection.
Viron's lead therapeutic candidate, VT-111, has demonstrated potent effects in preclinical suppression of chronic organ transplant rejection and, in a Phase IIa clinical trial of 48 patients, demonstrated reduced cardiac tissue damage in patients with ACS receiving cardiac stent implants. "It is remarkable to see such a small trial demonstrate such a strong, statistically significant impact in this target population," said Mr. Sullivan. "These trial results provide a compelling validation of Viron
|SOURCE Viron Therapeutics Inc.|
Copyright©2009 PR Newswire.
All rights reserved